By Nana O 
An experimental drug currently undergoing clinical trials as a cancer treatment could significantly enhance the effectiveness of first-line tuberculosis (TB) therapies by encouraging infected cells to undergo a less destructive form of cell death, according to groundbreaking research from Johns Hopkins Medicine. The findings, derived from extensive studies in mouse models of the lung-damaging disease, suggest a potential paradigm shift in TB treatment, aiming to reduce lung damage, prevent long-term pulmonary dysfunction, and improve outcomes for millions affected by this persistent global health threat. The research was supported by grants from the National Institutes of Health and published on March 27 in the esteemed journal Nature Communications.
A New Frontier in Host-Directed Therapy for Tuberculosis
The pursuit of more effective TB treatments has long been a critical objective for global health organizations. Current regimens, while life-saving, are often characterized by their lengthy duration, significant cost, and the lingering vulnerability of patients to relapse and irreversible lung scarring. This new research introduces the concept of a "host-directed therapy" – an approach that targets the body’s own cells rather than the infectious agent directly – as a powerful adjunct to existing antibiotic treatments.
"Current treatment regimens for TB are lengthy, expensive and leave patients vulnerable to relapse and lung scarring. Our research shows that adding in a host-directed therapy has extraordinary promise to solve these problems," stated Dr. Sanjay Jain, the study’s senior author, a pediatric infectious diseases specialist at Johns Hopkins Children’s Center, and a professor of pediatrics at the Johns Hopkins University School of Medicine. Dr. Jain’s extensive experience in infectious diseases has positioned him at the forefront of seeking innovative solutions for challenging global health issues.
The Global Burden of Tuberculosis and the Challenge of Drug Resistance
Tuberculosis remains a formidable global health adversary. Despite being preventable and treatable, the World Health Organization (WHO) reported an estimated 1.25 million deaths and 10.8 million new cases in 2023, once again likely making it the leading cause of death globally from an infectious disease. This stark figure underscores the ongoing urgency to improve treatment strategies.
Adding to this challenge, a growing number of TB infections are resistant to standard antibiotic treatments, including the "gold-standard" regimens. This drug resistance complicates patient recovery, necessitates more complex and often more toxic treatment protocols, and contributes to prolonged illness and higher mortality rates. The development of novel therapeutic approaches that can overcome these limitations is therefore paramount.
Understanding the Mechanisms of Cell Death in TB Infection
The bacterium responsible for TB, Mycobacterium tuberculosis (M. tuberculosis), orchestrates a complex interplay with infected host cells, significantly influencing the course of the disease. In the initial stages of infection, lung cells attempt to contain the spread of the bacteria through apoptosis, a precisely controlled and programmed process of cell self-destruction. This orderly demise prevents the release of harmful cellular contents and minimizes inflammation.
However, as TB progresses, the bacterium manipulates host cells to undergo a different, more chaotic form of cell death known as necrosis. Unlike apoptosis, necrosis is characterized by uncontrolled cellular breakdown, leading to widespread inflammation and significant damage to surrounding lung tissue. Dr. Jain aptly likens the difference to a controlled demolition of a building versus destruction by a bomb, highlighting the devastating impact of necrosis.
M. tuberculosis‘s Strategy: Hijacking Cell Death Pathways
The research reveals that M. tuberculosis actively promotes this destructive necrotic pathway by inducing infected "host cells" to overproduce Bcl-2, a crucial member of a family of proteins that inhibit apoptosis. By hijacking this normally protective molecular pathway, the bacterium creates a more permissive environment for its survival and proliferation.
"This hijack of a typically healthy molecular pathway has significant advantages for M. tuberculosis," explained Dr. Medha Singh, the study’s first author and a pediatric infectious diseases fellow at the Johns Hopkins University School of Medicine. "It promotes necrotic niches within the lung that prevent immune system attacks and allow the bacteria to multiply." These necrotic niches serve as sanctuaries for the bacteria, shielding them from the host’s immune defenses and facilitating their unchecked growth.
Navitoclax: A Cancer Drug Repurposed for TB
While previous studies had explored the potential of inhibiting Bcl-2 as a strategy to combat TB, this research marks a significant advancement by testing such a host-directed therapy in conjunction with a real-world TB treatment. The drug used in the study, navitoclax, is a potent Bcl-2 inhibitor currently undergoing clinical trials for the treatment of various cancers. Its mechanism of action involves accelerating programmed cell death, a process that could be leveraged to counteract the necrotic damage caused by TB.
The researchers initiated their experimental protocol by treating mice infected with M. tuberculosis using a standard TB treatment regimen comprising rifampin, isoniazid, and pyrazinamide, collectively known as RHZ. This regimen is considered the global standard of care for TB. In parallel, a subset of these mice also received navitoclax.
Promising Results: Reduced Damage, Enhanced Bacterial Clearance
The outcomes of this experimental intervention were compelling. Mice that received the combination therapy of RHZ and navitoclax demonstrated a remarkable 40% reduction in necrotic lesions within their lungs compared to those treated with RHZ alone. Furthermore, the spread of infection to other vital organs, such as the spleen, was significantly curtailed over the four-week treatment period in the combination therapy group.
Advanced imaging techniques, specifically positron emission tomography (PET) – a technology that is clinically translatable and was utilized for assessing apoptosis and fibrosis – provided further crucial insights. According to Dr. Laurence Carroll, a study author and assistant professor of radiology at the Johns Hopkins University School of Medicine, the addition of navitoclax doubled the amount of pulmonary apoptosis and reduced lung scarring by 40% when compared to standard TB treatments administered in isolation.
Perhaps most significantly, while navitoclax showed no direct impact on M. tuberculosis bacterial burden when used alone, the mice treated with both navitoclax and RHZ exhibited a dramatic 16-fold increase in their ability to decrease bacterial load. This synergistic effect highlights the potent combination of targeting both the host cell death pathway and the bacteria directly.
Implications for TB Survivors and Beyond
The implications of these findings extend far beyond the immediate treatment of active TB infection. The persistent lung damage and dysfunction that often plague TB survivors, a condition increasingly recognized as "post-TB lung disease," affects tens of millions worldwide and can lead to chronic respiratory problems and reduced quality of life. The ability of navitoclax to reduce lung scarring and promote gentler cell death could significantly mitigate these long-term consequences.
"These results suggest that navitoclax could offer similar effects for TB patients as well as patients with other chronic bacterial infections, such as Staphylococcus aureus and non-TB mycobacteria highly prevalent in the U.S.," Dr. Jain commented, broadening the potential scope of this therapeutic strategy.
The Path Forward: Clinical Trials and Future Research
The successful translation of these mouse model findings to human patients will necessitate rigorous clinical trials. Dr. Jain expressed optimism about the potential for such trials, particularly with the advancement of novel PET imaging approaches developed at the Johns Hopkins Center for Infection and Inflammation Imaging Research. These advanced imaging tools could provide early and precise readouts of the host-directed therapy’s efficacy and offer real-time visualization of lung scarring.
If future clinical trials prove successful, the integration of navitoclax or similar Bcl-2 inhibitors into standard TB treatment regimens could offer several transformative benefits:
- Shorter Treatment Durations: The enhanced efficacy of the combination therapy might allow for a reduction in the typical six-month daily course of antibiotic treatment, easing the burden on patients and healthcare systems.
- Reduced Lung Damage: By promoting apoptosis over necrosis, the therapy could significantly decrease the incidence and severity of lung scarring, thereby lowering the risk of post-TB lung disease.
- Improved Outcomes for Drug-Resistant TB: The synergistic effect observed in the mouse models suggests this approach could be particularly beneficial for patients with drug-resistant strains of TB, where treatment options are limited and outcomes are often poorer.
- Broader Applicability: The potential to address other chronic bacterial infections opens up new avenues for therapeutic development.
A Collaborative Effort
This pioneering research represents a significant collaborative effort involving a dedicated team of scientists at Johns Hopkins. Key contributors to the study include Mona Sarhan, Nerketa Damiba, Alok Singh, Andres Villabona-Rueda, Oscar Nino-Meza, Xueyi Chen, Yuderleys Masias-Leon, Carlos Ruiz-Gonzalez, Alvaro Ordonez, and Franco D’Alessio.
The research was made possible by substantial funding from the National Institutes of Health, specifically through grants R01-AI153349, R01-AI145435-A1, R56-AI179012-A1, R01-AI190038, and S10-OD030381-A1, underscoring the national importance placed on combating infectious diseases like TB.
Crucially, the study authors declared no conflicts of interest under the policies of the Johns Hopkins University School of Medicine, ensuring the objectivity and integrity of their findings. This research offers a beacon of hope, pointing towards a future where TB treatment is not only more effective in eradicating the bacteria but also gentler on the patient, preserving lung health and improving long-term quality of life.
